Erythrodermic Psoriasis Improved by Panitumumab, But Not BevacizumabNISHIZAWA, Aya; SATOH, Takahiro; YOKOZEKI, Hiroo et al.Acta dermato-venereologica. 2012, Vol 92, Num 4, pp 360-361, issn 0001-5555, 2 p.Article

Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapyMARTINELLI, E; DE PALMAR, R; ORDITURA, M et al.Clinical and experimental immunology (Print). 2009, Vol 158, Num 1, pp 1-9, issn 0009-9104, 9 p.Article

VECTIBIX^® (panitumumab, Amgen) Anticorps anti-EGFRRANCIERE, Fanny; DEBRIX, Isabelle; SELLE, Frédéric et al.Onko +. 2011, Vol 3, Num 23, pp 149-151, issn 2101-9495, 3 p.Article

Targeted Therapy in Colorectal Cancer: Current Status and Future Challenges : Targeted Cancer Therapies: Current Status and Future DirectionsKOUTRAS, A. K; STARAKIS, I; KYRIAKOPOULOU, U et al.Current medicinal chemistry. 2011, Vol 18, Num 11, pp 1599-1612, issn 0929-8673, 14 p.Article

Current role of antibody therapy in patients with metastatic colorectal cancerPFEIFFER, P; QVORTRUP, C; ERIKSEN, J. G et al.Oncogene (Basingstoke). 2007, Vol 26, Num 25, pp 3661-3678, issn 0950-9232, 18 p.Article

Interdisciplinary management of EGFR-inhibitor- induced skin reactions: a German expert opinionPOTTHOFF, K; HOFHEINZ, R; TRARBACH, T et al.Annals of oncology. 2011, Vol 22, Num 3, pp 524-535, issn 0923-7534, 12 p.Article

Association of progression-free survival with patient-reported outcomes and survival : results from a randomised phase 3 trial of panitumumabSIENA, S; PEETERS, M; WOLF, M et al.British journal of cancer. 2007, Vol 97, Num 11, pp 1469-1474, issn 0007-0920, 6 p.Article

Pharmacokinetic and Pharmacodynamic Perspectives on the Clinical Drug Development of PanitumumabYANG, Bing-Bing; LUM, Peggy; ALIN CHEN et al.Clinical pharmacokinetics. 2010, Vol 49, Num 11, pp 729-740, issn 0312-5963, 12 p.Article

Oncogenic mutations as predictive factors in colorectal cancerLIEVRE, A; BLONS, H; LAURENT-PUIG, P et al.Oncogene (Basingstoke). 2010, Vol 29, Num 21, pp 3033-3043, issn 0950-9232, 11 p.Article

Infusion reactions to the chimeric EGFR inhibitor cetuximab—change to the fully human anti-EGFR monoclonal antibody panitumumab is safeRESCH, G; SCHABERL-MOSER, R; KIER, P et al.Annals of oncology. 2011, Vol 22, Num 2, pp 486-487, issn 0923-7534, 2 p.Article

Dose and Schedule Study of Panitumumab Monotherapy in Patients with Advanced Solid MalignanciesWEINER, Louis M; BELLDEGRUN, Arie S; CRAWFORD, Jeffrey et al.Clinical cancer research. 2008, Vol 14, Num 2, pp 502-508, issn 1078-0432, 7 p.Article

Pharmacogenetics of EGFR and VEGF inhibitionPANDER, Jan; GELDERBLOM, Hans; GUCHELAAR, Henk-Jan et al.Drug discovery today. 2007, Vol 12, Num 23-24, pp 1054-1060, issn 1359-6446, 7 p.Article

Pharmacokinetics of panitumumab in a patient with liver dysfunction: a case reportKRENS, L. L; BAAS, J. M; DE JONG, F. A et al.Cancer chemotherapy and pharmacology. 2014, Vol 73, Num 2, pp 429-433, issn 0344-5704, 5 p.Article

Panitumumab a novel drug in cancer treatmentCARTENI, G; FIORENTINO, R; VECCHIONE, L et al.Annals of oncology. 2007, Vol 18, issn 0923-7534, vi16-vi21, SUP6Conference Paper

Inhibition de la voie de signalisation de l'Epidermal Growth Factor Receptor: anticorps monoclonaux (partie I)PERKINS, G; MASSARD, C.La Lettre du cancérologue (Boulogne). 2011, Vol 20, Num 7, issn 1165-113X, I-VIArticle

Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal CancerBARDELLI, Alberto; SIENA, Salvatore.Journal of clinical oncology. 2010, Vol 28, Num 7, pp 1254-1261, issn 0732-183X, 8 p.Article

Risk of anti-EGFR monoclonal antibody-related skin rash: an up-to-date meta-analysis of 25 randomized controlled trialsQI, Wei-Xiang; SUN, Yuan-Jue; ZAN SHEN et al.Journal of chemotherapy (Testo stampato). 2014, Vol 26, Num 6, pp 359-368, issn 1120-009X, 10 p.Article

Accurate KRAS mutation testing for EGFR-targeted therapy in colorectal cancer: emphasis on the key role and responsibility of pathologistsHOORENS, A; JOURET-MOURIN, A; SEMPOUX, C et al.Acta gastro-enterologica belgica (English ed.). 2010, Vol 73, Num 4, pp 497-503, issn 1784-3227, 7 p.Conference Paper

Panitumumab―FOLFOX4 Treatment and RAS Mutations in Colorectal CancerDOUILLARD, Jean-Yves; OLINER, Kelly S; RIVERA, Fernando et al.The New England journal of medicine. 2013, Vol 369, Num 11, pp 1023-1034, issn 0028-4793, 12 p.Article

Improving disease control in advanced colorectal cancer: Panitumumab and cetuximabRODRIGUEZ, Javier; VIUDEZ, Antonio; PONZ-SARVISE, Mariano et al.Critical reviews in oncology/hematology. 2010, Vol 74, Num 3, pp 193-202, issn 1040-8428, 10 p.Article

Clinical results of EGFR-targeted therapies in advanced colorectal cancerMAIELLO, Evaristo; GEBBIA, Vittorio; MANZIONE, Luigi et al.European journal of cancer. Supplement (1990). 2008, Vol 6, Num 14, pp 64-69, issn 1359-6349, 6 p.Conference Paper

Les indications et le maniement des anticorps anti-EGFR dans les cancers colorectaux = Therapeutic use and handling of anti-EGFR antibodies in colorectal cancersANDRE, Thierry.Hépato-gastro (Montrouge). 2008, Vol 15, Num SEPT, pp 18-22, issn 1253-7020, 5 p., NSArticle

Panitumumab monotherapy in patients with previously treated metastatic colorectal cancerRANDOLPH HECHT, J; PATNAIK, Amita; BERLIN, Jordan et al.Cancer. 2007, Vol 110, Num 5, pp 980-988, issn 0008-543X, 9 p.Article

A comparison of in vitro methods for determining the membrane receptor expression in cell linesNOVY, Zbynek; BARTA, Pavel; MANDIKOVA, Jana et al.Nuclear medicine and biology. 2012, Vol 39, Num 7, pp 893-896, issn 0969-8051, 4 p.Article

Panitumumab et autres anti-EGFR: ulcérations de la cornéeLa Revue Prescrire. 2012, Vol 32, Num 348, issn 0247-7750, p. 748Article